We added the following clinical trials to Metastatic Trial Search for March 2025. To see all clinical trials, please visit Metastatic Trial Search.

ER or PR Positive Trials

• Radioactive Drug with Chemotherapy for Metastatic ER+, HER2- or HER2 Low, GRPR+ Breast Cancer
• Zunsemetinib Targeted Therapy with Chemotherapy for Metastatic HR+, HER2- Breast Cancer with Bone Metastasis
• OP-3136 Targeted Therapy for Advanced ER+, HER2- Breast Cancer
• MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer
• PET/CT Scans to Detect and Monitor Metastatic ER+, HER2- Lobular Breast Cancer

HER2 Positive or HER2 Negative or HER2 Low Trials

• PHESGO Targeted Therapy After Enhertu ADC for People with Advanced HER2+ Breast Cancer
• Vaccine for Metastatic HER2+, HER2 Low, or EGFR+ Breast Cancer
• IAM1363 Targeted Therapy for Advanced HER2+ or HER2 Mutated Breast Cancer
• Utidelone Chemotherapy for Metastatic HER2- or HER2 Low Breast Cancer with Brain Metastases

Triple Negative Trials

• TUB-030 Antibody Drug Conjugate for Advanced Triple Negative and HR+, HER2- Breast Cancer
• LP-184 Chemotherapy for Advanced Triple Negative Breast Cancer or Breast Cancer with DNA Damage Mutations
• IPH4502 Antibody Drug Conjugate for Advanced Triple Negative Breast Cancer

Other Stage IV Trials

• Sotorasib Targeted Therapy for Metastatic Breast Cancer with KRAS G12C+ Brain Metastases
• Decreasing Doses of Dexamethasone to Reduce Side Effects After Brain Surgery for People with Breast Cancer Brain Metastases
• REM-001 Photodynamic Therapy for Advanced Breast Cancer That Spread to the Skin
• LNCB74 Antibody Drug Conjugate for Advanced Breast Cancer

Last Modified on March 3, 2025